Bioventix (BVXP) Full Year results June 2016 interview

Length: c 20 mins

Peter Harrison, CEO, talks through the latest FY results 30 June 2016 with @tamzinpiworld. He expands on the success of Vitamin D and its future prospects, together with the positive impact of foreign exchange.

He goes on to talk about the NT proBNP licence, which comes to an end July 2017, with all revenue (c.£750k) being lost from August 2017 onwards. Peter is confident Troponin, will launch at some point in 2017, based on all the updates given by Siemens, although timing is in Siemen’s hand. He has estimated July 2017 to start roll-out, it being the mid point of the year. He mentions the initial and on-going revenue expectations for Troponin.

Peter briefly discusses other antibodies already producing revenue, and future developments for the medium term. Cardinor, Norway is not discussed, since this is unlikely to result in revenues over the near term.

Peter answers questions on a few potential threats, including consolidation of customers and any new technologies that could disrupt their market.

Finally, he talks about staff motivation, and financial reward.

Presentation slides can be viewed here (a new window will open).

Videos from Bioventix

Bioventix (BVXP) Full Year results June 2016 interview
4
21:17

Bioventix (BVXP) Full Year results June 2016 interview

Length: c 20 mins Peter Harrison, CEO, talks through the latest FY results 30 June 2016 with @tamzinpiworld. He expands on the success of Vitamin D and its future prospects, together with the positive impact of foreign exchange. He goes on to talk about the NT proBNP licence, which comes to an end July 2017, […]
Bioventix – BVXP –  Company overview
07:01

Bioventix – BVXP – Company overview

Introduction to Bioventix (BVXP) by Peter Harrison, CEO Length: c. 6 mins Peter Harrison, CEO, tells us what Bioventix does, and discusses the business model. Essentially BVXP develops antibodies for use in different blood testing machines manufactured by the big names: Roche, Siemens, Abbot, etc. He goes into detail about BVXP antibodies types, and why […]
Bioventix BVXP ShareSoc Richmond 6 6 16
4

Bioventix BVXP ShareSoc Richmond 6 6 16

Peter Harrison CEO Bioventix (BVXP) ShareSoc Richmond 6.6.16 A succinct presentation to understand what BVXP do. • The product • Revenue streams • Stickiness of revenue • Timelines to develop revenue streams • Barriers to entry • Threats • The future A sense of the culture of the company The journey of the historic research […]

You might be interested in

LEAVE YOUR COMMENT

Your email address will not be published. Required fields are marked *